• Publications
  • Influence
ERGIC-53, a membrane protein of the ER-Golgi intermediate compartment, carries an ER retention motif.
Overlapping cDNAs encoding the entire human ERGIC-53, a 53 kDa membrane protein of the ER-Golgi intermediate compartment, have been isolated and their nucleotide sequence determined. The isolatedExpand
  • 151
  • 11
Adventure Therapy—Critical Questions
This article explores the basic definition of adventure therapy, which leads to the critical questions of whether adventure therapy is a profession, and if there should be a certification system. InExpand
  • 33
  • 11
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct
Certain bispecific antibodies exhibit an extraordinary potency and efficacy for target cell lysis by eliciting a polyclonal T‐cell response. One example is a CD19‐/CD3‐bispecific single‐chainExpand
  • 261
  • 10
Targeting of protein ERGIC-53 to the ER/ERGIC/cis-Golgi recycling pathway
ERGIC-53 is a lectin-type membrane protein that continuously recycles between the ER, ER-Golgi intermediate compartment (ERGIC) and the cis- Golgi. To identify the targeting signals that mediate thisExpand
  • 110
  • 8
  • PDF
ERGIC-53 is a functional mannose-selective and calcium-dependent human homologue of leguminous lectins.
Based on sequence homologies with leguminous lectins, the intermediate compartment marker ERGIC-53 was proposed to be a member of a putative new class of animal lectins associated with the secretoryExpand
  • 150
  • 6
Mistargeting of the Lectin ERGIC-53 to the Endoplasmic Reticulum of HeLa Cells Impairs the Secretion of a Lysosomal Enzyme
ERGIC-53, a homo-oligomeric recycling protein associated with the ER–Golgi intermediate compartment (ERGIC), has properties of a mannose-selective lectin in vitro, suggesting that it may function asExpand
  • 138
  • 3
  • PDF
Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy
Recombinant monoclonal antibodies are beginning to revolutionize cancer therapy. In combination with standard chemotherapy, high response rates have been reported with antibodies of the human IgG1Expand
  • 58
  • 2
A dual role for COOH-terminal lysine residues in pre-Golgi retention and endocytosis of ERGIC-53.
ERGIC-53 (former designation, p53) is a 53-kDa nonglycosylated, dimeric, and hexameric type I membrane protein that has been established as a marker protein for a tubulovesicular intermediateExpand
  • 32
  • 2
  • PDF
A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration.
GM-CSF (granulocyte-macrophage colony stimulating factor) plays a central role in inflammatory processes. Treatment with antibodies neutralizing murine GM-CSF showed significant therapeutic effectsExpand
  • 27
  • 1